Search

Innate immune dysfunction persists in HIV+ individuals despite effective combination antiretroviral therapy (cART). We recently demonstrated that an adaptive-like CD56dim NK cell population lacking the signal transducing protein FcRγ is expanded in HIV+ individuals. Here, we analyzed a cohort of HIV+ men who have sex with men (MSM, n=20) at baseline and following 6, 12 and 24 months of cART and compared them with uninfected MSM (n=15) to investigate the impact of cART on NK cell dysfunction. Proportions of NK cells expressing markers of early (CD69+) and late (HLA-DR+/CD38+) activation were elevated in cART-naïve HIV+ MSM (p=0.004 and 0.015, respectively), as were FcRγ-NK cells (p=0.003). Using latent growth curve modeling, we show that cART did not reduce levels of FcRγ- NK cells (p=0.115) or activated HLA-DR+/CD38+ NK cells (p=0.129) but did reduce T cell and monocyte activation (p<0.001 for all). Proportions of FcRγ- NK cells were not associated with NK cell, T cell, or monocyte activation, suggesting different factors drive CD56dim FcRγ- NK cell expansion and immune activation in HIV+ individuals. While proportions of activated CD69+ NK cells declined significantly on cART (p=0.003), the rate was significantly slower than the decline of T cell and monocyte activation, indicating a reduced potency of cART against NK cell activation. Our findings indicate that 2 years of suppressive cART have no impact on CD56dim FcRγ- NK cell expansion and that NK cell activation persists after normalization of other immune parameters. This may have implications for the development of malignancies and co-morbidities in HIV+ individuals on cART. [ABSTRACT FROM AUTHOR]

Innate immune dysfunction persists in HIV + individuals despite effective combination antiretroviral therapy (cART). We recently demonstrated that an adaptive-like CD56 dim NK cell population lacking the signal transducing protein FcRγ is expanded in HIV + individuals. Here, we analyzed a cohort of HIV + men who have sex with men (MSM, n  = 20) at baseline and following 6, 12, and 24 months of cART and compared them with uninfected MSM ( n  = 15) to investigate the impact of cART on NK cell dysfunction. Proportions of NK cells expressing markers of early (CD69 + ) and late (HLA-DR + /CD38 + ) activation were elevated in cART-naïve HIV + MSM ( p  = 0.004 and 0.015, respectively), as were FcRγ - NK cells ( p  = 0.003). Using latent growth curve modeling, we show that cART did not reduce levels of FcRγ - NK cells ( p  = 0.115) or activated HLA-DR + /CD38 + NK cells ( p  = 0.129) but did reduce T cell and monocyte activation ( p  < 0.001 for all). Proportions of FcRγ - NK cells were not associated with NK cell, T cell, or monocyte activation, suggesting different factors drive CD56 dim FcRγ - NK cell expansion and immune activation in HIV + individuals. While proportions of activated CD69 + NK cells declined significantly on cART ( p  = 0.003), the rate was significantly slower than the decline of T cell and monocyte activation, indicating a reduced potency of cART against NK cell activation. Our findings indicate that 2 years of suppressive cART have no impact on CD56 dim FcRγ - NK cell expansion and that NK cell activation persists after normalization of other immune parameters. This may have implications for the development of malignancies and co-morbidities in HIV + individuals on cART.